Introduction
============

Systemic sclerosis (SSc) is an autoimmune disease of the connective tissue characterized by excessive fibrosis of the dermis and vascular damage. It also affects internal organs, such as the lung, gastrointestinal, and vascular systems \[[@B1]\]. SSc is a complex polygenic disease in which environmental and genetic factors are involved in the susceptibility to this disease. Candidate gene and genome-wide association studies (GWASs) performed in SSc have identified new loci implicated in the susceptibility to SSc \[[@B2]\]. Nevertheless, the complete genetic components of SSc remain unknown.

CD40 is a member of the tumor necrosis factor receptor superfamily (TNFR), and it is expressed on the surface of several immune and nonhematopoietic cells, such as B cells, macrophages, dendritic cells, fibroblasts, and endothelial cells in certain pathogenic conditions \[[@B3]\]. Its ligand, CD40LG (CD154), is expressed mainly on the surface of CD4^+^ T cells. CD40-CD40LG interactions are necessary for the activation of both humoral and cellular immune responses \[[@B3]\]. The CD40-CD40LG pathway has been suggested to play an important role in the pathogenesis of autoimmune diseases \[[@B4]\]. An increase of soluble CD40LG (sCD40LG) has been observed in many autoimmune diseases, such as systemic lupus erythematosus (SLE) \[[@B5]\], rheumatoid arthritis (RA) \[[@B6]\], and Graves disease (GD) \[[@B7]\]. Interestingly, patients with SSc and limited cutaneous disease have higher levels of sCD40LG in the plasma than those of the diffuse cutaneous disease \[[@B8]\]. Similarly, high levels of CD40 protein were observed in both the plasma \[[@B9]\] and the cell surface of skin fibroblasts \[[@B10]\] from SSc patients. In addition, previous studies reported the association of *CD40*polymorphisms with susceptibility to a number of autoimmune diseases, such as GD \[[@B11]\], multiple sclerosis \[[@B12]\], RA \[[@B13],[@B14]\], Crohn disease \[[@B15]\], and with visual ischemic manifestations in individuals with biopsy-proven giant cell arteritis \[[@B16]\]. Nevertheless, in the case of SLE, contradictory data exist \[[@B17]-[@B19]\]. In addition, mutations of *CD40LG*were observed in patients with the hyper-immunoglobulin M (IgM) syndrome \[[@B20]\], and genetic variations located at the 3UTR of the *CD40LG*gene were associated with two autoimmune diseases, SLE \[[@B21]\] and RA \[[@B22]\].

Taking into account these considerations, we aimed to investigate the potential association of *CD40*and *CD40LG*genes polymorphism with SSc.

Materials and methods
=====================

Patients
--------

In total, 2,670 SSc patients and 3,245 healthy individuals from four European populations were included in this study (Spain: cases, 1,103; controls, 1,610; Germany: cases, 554; controls, 437; The Netherlands: cases, 380; controls, 489; Italy: cases, 633; controls, 709). All the patients fulfilled the 1980 American College of Rheumatology (ACR) classification criteria for SSc \[[@B23]\]. Limited cutaneous disease (lcSSc) was defined as definite skin thickening confined to the distal extremities, whereas cases of diffuse cutaneous disease (dcSSc) required also the involvement of skin proximal to the knees and elbow \[[@B24],[@B25]\]. Measurement of main SSc-specific autoantibodies, anti-centromere antibodies (ACAs), and anti-topoisomerase I antibodies (ATAs), was performed by using standard methods. Pulmonary fibrosis data were investigated by using a computed tomography scan. The main features of all populations included in this study were previously reported \[[@B26]-[@B28]\].

Patients and controls were included in the study after written informed consent, according to the declaration of Helsinki. The study was approved by local ethical committees from all the participating centers.

SNPs selection and genotyping
-----------------------------

DNA from patients and controls was obtained by using standard methods. *CD40*is located on chromosome 20q13.12. Three single-nucleotide polymorphisms (SNPs) of *CD40*associated with other autoimmune diseases were selected. rs1883832 had been associated with GD \[[@B11]\]; whereas rs4810485, in linkage disequilibrium with rs1883832 (*r^2^*= 0.95), has been identified as a new risk factor for RA \[[@B13]\]. Furthermore, rs1535045 has been associated with subclinical atherosclerosis in diabetes families \[[@B29]\]. *CD40LG*is found on chromosome Xq26.3. Two genetic variants located in 5 UTR (rs3092952) and 3 UTR (rs3092920) of *CD40LG*(*r^2^*= 0.38) were selected. These SNPs are located in different haplotype blocks of *CD40LG*\[[@B17]\]. The variant rs3092920 is located near the 3 UTR microsatellite, which was previously associated with RA and SLE \[[@B21],[@B22]\]; whereas rs3092952 is a functional variant related to the levels of sCD40LG in plasma \[[@B30]\].

All SNPs were genotyped in the same center by using a TaqMan SNP genotyping assay in a 7900HT Real-Time polymerase chain reaction (PCR) system, by following the conditions recommended by the manufacturer (Applied Biosystems, Foster City, CA, USA). About 10% of the patients were genotyped twice to verify the genotyping consistency, showing 99% identical genotypes. The genotyping call-rate success was \>95% for both cases and controls in all populations.

Statistical analysis
--------------------

The Hardy-Weinberg equilibrium (HWE) was tested by means of the Fisher Exact test or χ^2^ when necessary. The case-control association study was performed by using a 2 × 2 contingency table with χ^2^ to obtain *P*values, odds ratios (ORs), and 95% confidence intervals (CIs). Combined OR was calculated according to a fixed-effects model (Mantel-Haenszel meta-analysis), and the heterogeneity of OR among all populations was calculated by using the Breslow-Day test. *P*values \<0.05 were considered statistically significant. Statistical analyses were carried out with PLINK \[[@B31]\].

The estimation of the power of the study to detect an effect of a polymorphism in disease susceptibility was performed by using The CaTS Power Calculator software \[[@B32]\].

Results
=======

*CD40*gene variants in SSc
--------------------------

Three *CD40*polymorphisms were genotyped in four European populations. First, we analyzed the cohorts individually and then combined the samples in a pooled analysis. Table [1](#T1){ref-type="table"} describes allelic distribution of the three SNPs in the pooled analysis, and Additional file [1](#S1){ref-type="supplementary-material"}, Table S1-3 contains detailed data for each population. Both cases and controls were confirmed to be in HWE in all populations. No evidence of association between *CD40*polymorphisms and susceptibility to SSc was observed in the pooled analysis (allelic *P*value rs1883832: *P*= 0.61; OR, 1.02; 95% CI, 0.94 to 1.11; rs4810485: *P*= 0.42; OR, 1.04; 95% CI, 0.95 to 1.13; rs1535045: *P*= 0.275; OR, 0.95; 95% CI, 0.88 to 1.04).

###### 

Pooled analysis of *CD40*polymorphisms

  ------------------------------------------------------------------------------------------------------------
  SNP         Change   Samples set          *N*     Minor allele,\    *P*value   OR \[95% CI\]        *P-BD*
                                                    no. (frequency)                                   
  ----------- -------- -------------------- ------- ----------------- ---------- -------------------- --------
  rs1883832   T/C      Controls             3,138   1,427 (0.277)                                     

                       SSc                  2,605   1,424 (0.274)     0.610      1.02 \[0.94-1.11\]   0.904

                       lcSSc                1,758   987 (0.276)       0.246      1.06 \[0.96-1.16\]   0.496

                       dcSSc                860     451 (0.271)       0.683      0.97 \[0.86-1.10\]   0.446

                       ACA +                1,077   592 (0.261)       0.879      1.01 \[0.90-1.13\]   0.355

                       ATA +                716     416 (0.293)       0.108      1.11 \[0.98-1.26\]   0.946

                       Pulmonary fibrosis   702     394 (0.278)       0.433      1.05 \[0.92-1.20\]   0.802

                                                                                                      

  rs4810485   G/T      Controls             3,122   1,652 (0.272)                                     

                       SSc                  2,560   1,388 (0.274)     0.420      1.04 \[0.95-1.13\]   0.935

                       lcSSc                1,736   967 (0.277)       0.155      1.07 \[0.97-1.18\]   0.481

                       dcSSc                839     436 (0.269)       0.817      0.99 \[0.87-1.12\]   0.600

                       ACA +                1,071   580 (0.257)       0.844      1.01 \[0.90-1.13\]   0.399

                       ATA +                699     402 (0.292)       0.080      1.12 \[0.99-1.28\]   0.890

                       Pulmonary fibrosis   682     375 (0.272)       0.483      1.05 \[0.92-1.20\]   0.605

                                                                                                      

  rs1535045   T/C      Controls             3,147   1,595 (0.247)                                     

                       SSc                  2,585   1,272 (0.243)     0.275      0.95 \[0.88-1.04\]   0.560

                       lcSSc                1,749   860 (0.251)       0.375      0.96 \[0.87-1.05\]   0.334

                       dcSSc                850     411 (0.228)       0.275      0.93 \[0.82-1.06\]   0.746

                       ACA +                1,075   525 (0.241)       0.348      0.95 \[0.84-1.06\]   0.844

                       ATA +                707     369 (0.264)       0.669      1.03 \[0.90-1.18\]   0.640

                       Pulmonary fibrosis   696     340 (0.250)       0.396      0.94 \[0.82-1.08\]   0.028
  ------------------------------------------------------------------------------------------------------------

Controls are used as reference for all comparisons. All *P*values have been calculated for the allelic model by using the Mantel-Haenszel test under fixed effect. P_BD, *P*value by the Breslow-Day method.

To investigate the possible influence of the *CD40*polymorphisms with clinical features, we stratified the patients according to the main SSc manifestations. However, we did not observe evidence of association after comparing lcSSc and dcSSc with healthy subjects (see Table [1](#T1){ref-type="table"}). Additionally, we compared the presence of SSc-specific autoantibodies in the patients with the healthy individuals, but no significant differences were observed (Table [1](#T1){ref-type="table"}). Likewise, no significant association was observed when patients with pulmonary fibrosis were compared with healthy controls (Table [1](#T1){ref-type="table"}).

*CD40LG*gene variants in SSc
----------------------------

Because *CD40LG*is located on the X-chromosome and shows the sexual bias of this disease, we performed the analysis separately for each gender. Table [2](#T2){ref-type="table"} shows the allelic frequencies in SSc females of the two *CD40LG*polymorphisms in the pooled analysis, and Additional file [1](#S1){ref-type="supplementary-material"}, Table S4-5 shows the frequencies for each population. Deviations from HWE were not observed. With the Mantel-Haenzel test, the genotype and allele frequencies were similar between SSc patients and healthy individuals (allelic *P*value rs3092952: *P*= 0.44; OR, 0.96; 95% CI, 0.85 to 1.07; rs3092920: *P*= 0.565; OR, 0.96; 95% CI, 0.83 to 1.11). No statistical differences were observed when SSc patients were stratified by common subtype of the disease, the presence of SSc-specific autoantibodies, and pulmonary fibrosis (Table [2](#T2){ref-type="table"}).

###### 

Pooled analysis of *CD40LG*polymorphisms in female SSc patients and controls

  -------------------------------------------------------------------------------------------------------------
  SNP         Change   Samples set          *N*     Minor allele,\    *P*value   OR \[95% CI\]        *P*\_BD
                                                    no. (frequency)                                   
  ----------- -------- -------------------- ------- ----------------- ---------- -------------------- ---------
  rs3092952   G/A      Controls             1,795   655 (0.176)                                       

                       SSc                  2,082   735 (0.186)       0.440      0.96 \[0.85-1.07\]   0.18

                       lcSSc                1,446   515 (0.188)       0.592      0.97 \[0.85-1.10\]   0.12

                       dcSSc                635     219 (0.179)       0.307      0.92 \[0.77-1.09\]   0.73

                       ACA +                924     338 (0.195)       0.978      1.00 \[0.87-1.16\]   0.06

                       ATA +                533     184 (0.188)       0.375      0.92 \[0.77-1.11\]   0.50

                       Pulmonary fibrosis   542     198 (0.173)       0.735      0.97 \[0.81-1.16\]   0.41

                                                                                                      

  rs3092920   T/G      Controls             1,789   376 (0.107)                                       

                       SSc                  2,104   426 (0.105)       0.565      0.96 \[0.83-1.11\]   0.89

                       lcSSc                1,456   310 (0.112)       0.929      1.01 \[0.86-1.18\]   0.97

                       dcSSc                647     116 (0.091)       0.120      0.84 \[0.67-1.05\]   0.36

                       ACA +                939     201 (0.111)       0.924      1.01 \[0.84-1.21\]   0.48

                       ATA +                541     106 (0.103)       0.434      0.91 \[0.73-1.15\]   0.86

                       Pulmonary fibrosis   549     124 (0.106)       0.657      1.05 \[0.84-1.31\]   0.55
  -------------------------------------------------------------------------------------------------------------

Controls are used as reference for all comparisons. All *P*values have been calculated for the allelic model by using the Mantel-Haenszel test under fixed effect. *P*\_BD, *P*value by the Breslow-Day method.

In addition, we analyzed these two polymorphisms in SSc male patients, but no evidence of association was found in the combined analyses (see Additional file [1](#S1){ref-type="supplementary-material"}, Table S6-7). However, these results should be interpreted with caution because the statistical power is insufficient to detect association because of low sample size.

Discussion
==========

The important role of the CD40-CD40LG pathway in autoimmunity \[[@B4]\], together with the association of the *CD40*gene with a number of autoimmune diseases, prompted us to investigate for the first time the contribution of *CD40*and *CD40LG*genes in SSc.

Despite the previous findings \[[@B8]-[@B10]\], we observed no evidence of association of the *CD40*or *CD40LG*gene variants analyzed with SSc. It was also the case when SSc patients were stratified by the SSc clinical subtypes, specific autoantibodies, or pulmonary fibrosis. We analyzed a large European population from four different countries to increase the robustness of the study. In this regard, our combined study had an estimated power of 92% to detect the relative risk, with OR of 1.15 obtained for RA susceptibility \[[@B13],[@B14]\], at the 5% significance level. Therefore, it seems unlikely that the absence of association found in our study would be due to Type II error.

In the present study, we analyzed the functional *CD40*-1C/T polymorphism (rs1883832). This genetic variant is located at -1 from the ATG, within a Kozak sequence, a stretch of nucleotides essential for translation that flanks the start codon in vertebrate genes \[[@B33]\]. The presence of a major allele (C) in this SNP is associated with the increase of the efficiency of CD40 translations \[[@B11]\]. Although quantitative differences between CD40 mRNA and proteins have been observed in SSc skin fibroblasts \[[@B10]\], the absence of association found for rs1883832 suggests that this variant might not affect the translation of *CD40*mRNA. This process may be upregulated in these abnormal skin fibroblasts, or other genes of the *CD40*signaling pathway may influence the *CD40*expression. However, functional studies in this way should be constructed before excluding an association between this variant and the *CD40*expression in SSc.

Although *CD40*might be a common susceptibility locus for some autoimmune diseases \[[@B11]-[@B16]\], our results do not suggest an important role of *CD40*in the susceptibility to SSc. Several genes have been recently disclosed to play a function in the susceptibility to autoimmune diseases, suggesting that these diseases share a genetic background \[[@B34]\]. However, these loci may not be universal genetic factors for autoimmune disorders; therefore, the autoimmunity might result from specific and multiple pleiotropic effects \[[@B19]\]. Also, other genes are unique for each disease, reflecting a specific etiology \[[@B19],[@B34]\]. Additional studies are required for the identification of specific and shared genetic pathways that contribute to a better understanding of the pathogenesis of the autoimmune diseases.

The role of the *CD40LG*in the susceptibility to autoimmune diseases has not been investigated as broadly as that of *CD40*, mainly because this gene is located on the × chromosome. The different prevalences of these diseases in both genders can suggest that genes located on the × chromosome could be susceptibility factors in autoimmune diseases; however, few studies analyzed polymorphisms on this chromosome. Mutations on this gene are associated with X-linked hyper-IgM syndrome, a familial genetic disorder characterized by an increase of IgM level and a decrease of IgG and IgA \[[@B20]\], but in SLE, no evidence of association has been found \[[@B17]\]. Similarly, our results show that the *CD40LG*gene may not be SSc susceptibility loci.

Conclusions
===========

Our results do not suggest an important role of *CD40*and *CD40LG*genes in the susceptibility to SSc. Additional studies are required to draw firm conclusions about the exact role of the *CD40*and *CD40LG*genes in SSc susceptibility because other variants might be involved in SSc. Future studies involving other genes of the CD40-CD40LG pathway should be conducted to elucidate fully the contribution of this pathway in the pathogenesis of SSc.
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